COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: : Ivermectin(200 mcg/Kg, PO, Once) to patient and Placebo(PO,Once) to other members of family. Intervention 2: Intervention group: Ivermectin(200 mcg/Kg, PO, Once)
Sponsors
Akam Tejarat Fartak Farasoo Company
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Healthy individuals exposed directly and constantly with COVID-19 patients. COVID-19 patients who their disease is confirmed by RT-PCR test and low to moderate severity(Grade94 who fit outpatient protocol. Having consent for participating in study
Exclusion criteria
Exclusion criteria: Pregnant or breastfeeding women individuals with a certain CNS disease Individuals with an uncontrolled disease(Asthma, COPD, cardiovascular disease, diabetes, Kidney or Liver dysfunction, Cancer, Hepatitis, AIDS, Immunodeficiency) Patients receiving immuno suppressive drugs individuals receiving any P-450 or P-gp blockers or any medication interacting with ivermectin patients under antiviral therapy individuals receiving any Corticosteroid(Inhaling, PO or Injection) any known sensitivity to Ivermectin or starch or history of lactose intolerability(for Placebo) individuals with positive SARS-CoV-2 specific antibody
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients in family members. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Follow-up and questionnaire from the patient about the symptoms of the Covid 19.;Duration of illness. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Follow-up and questionnaire from the patient about the symptoms of the Covid 19.;Severity of disease. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Follow-up and questionnaire from the patient about the symptoms of the Covid 19. | — |
Secondary
| Measure | Time frame |
|---|---|
| Considering the drug side effects during the study. Timepoint: 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Follow-up and questionnaire from the patient about the symptoms of the Covid 19.;Considering the changes in serum antibody level of IgA. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Serologic test-ELISA.;Considering the changes in serum antibody levels of IgM. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Serologic test-ELISA.;Considering the changes in serum antibody levels of IgG. Timepoint: The day of zero and 3 days after taking the drug, then every week for a month (until complete recovery of family members)days 0, 3, 7, 14, 21, 28. Method of measurement: Serologic test-ELISA.;Duration of the illness with recheck of Rt-PCR at days. Timepoint: The day of 3 and 7 after taking the drug. Method of measurement: Rt-PCR test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNematollah Gheibi
Qazvin University of Medical Sciences
Outcome results
None listed